BridgeMD
New treatment option for Venous Thromboembolism
Official title Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER )
ClinicalTrials.gov ID: NCT06731244
What this study is testing
- What it's testing
- Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a frequent disease and the third most common cause of cardiovascular death in the world after myocardial infarction and stroke. Anticoagulant therapy drastically reduces the risk of early VTE recurrence and death, but it exposes patients to a substantial risk of bleeding.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient \> or = 18 years,
- Patient with a first episode of symptomatic unprovoked pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT) treated for 3 to 6...
- Signed informed consent.
You likely can't join if
- Unable or refusal to give informed consent,
- Isolated distal DVT,
- Isolated sub-segmental PE
- Previous unprovoked VTE
- Known CTEPH
- Indication for anticoagulation other than DVT or PE (e.g.; atrial fibrillation, mechanic valves…),
See the full eligibility criteria
- Patient \> or = 18 years,
- Patient with a first episode of symptomatic unprovoked pulmonary embolism (PE) and/or proximal deep vein thrombosis (DVT) treated for 3 to 6 uninterrupted months with full dose anticoagulant therapy,
- Signed informed consent.
- Unable or refusal to give informed consent,
- Isolated distal DVT,
- Isolated sub-segmental PE
- Previous unprovoked VTE
- Known CTEPH
- Indication for anticoagulation other than DVT or PE (e.g.; atrial fibrillation, mechanic valves…),
- Interruption of anticoagulation for 14 days or more before the inclusion,
- Active cancer of less than 24 months,
- Current pregnancy,
- Life expectancy \<18 months (e.g.; patients with an end-stage chronic disease)
- Not affiliated to national insurance, social security (only for France)
The study team makes the final eligibility decision.
Where it's taking place
- Brest, France, France
- Amiens, France
- Angers, France
- Clamart, France
- Clermont-Ferrand, France
- Colombes, France
- Dijon, France
- Le Mans, France
- Lyon, France
- Marseille, France
- Montpellier, France
- Nancy, France
- Nantes, France
- Nîmes, France
- Paris, France
- Rennes, France
- Saint-Etienne, France
- Strasbourg, France
- Toulouse, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brest, France, France; Amiens, France; Angers, France; Clamart, France; Clermont-Ferrand, France; Colombes, France and 13 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.